Please assess the completion status of the following clinical trial:

Trial Title: Neuroprotection With Phenytoin in Optic Neuritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute optic neuritis~* Visual acuity in affected eye ≤ 6/12~* Corrected vision in normal eye ≥ 6/6~* No history of optic neuritis or other ocular disease in either eye~* ≤ 14 days since onset of visual loss~Exclusion Criteria:~* Contraindication or known allergy to Phenytoin~* Contraindication to MRI~* Use of a calcium channel or sodium channel blocker in the past 2 months~* Corticosteroid use in the past 2 months~* Tysabri infusion in the past 3 months~* MS with major temperature dependent disability~* Relapsing remitting MS of greater than 10 yrs duration or EDSS\>3~* Pregnancy~* Breast Feeding~* Significant cardiac, renal or liver abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- phenytoin (Type: EXPERIMENTAL): active arm of trial 1:1 allocation active versus placebo
- placebo (Type: PLACEBO_COMPARATOR): 1:1 allocation active versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).